Literature DB >> 7034916

Treatment of nephrotic edema with bumetanide.

G Lemieux, M Beauchemin, A Gougoux, P Vinay.   

Abstract

In a crossover study bumetanide, 2 to 6 mg/d, was compared with furosemide, 40 to 160 mg/d, in the treatment of 10 patients with the nephrotic syndrome and massive edema. The two drugs, which both act on the loop of Henle, were found to be equally effective. Patients with renal insufficiency responded poorly to both drugs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7034916      PMCID: PMC1862648     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  7 in total

1.  Use of bumetanide in the treatment of ascites due to liver disease.

Authors:  P J Moult; M R Lunzer; D B Trash; S Sherlock
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

2.  Some aspects of the renal action and clinical pharmacology of oral bumetanide in man.

Authors:  E Bourke
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

3.  Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Authors:  K H Olesen; B Sigurd; E Steiness; A Leth
Journal:  Acta Med Scand       Date:  1973 Jan-Feb

4.  Bumetanide in the treatment of hepatic ascites. A short and long-term study.

Authors:  H Ring-Larsen
Journal:  Acta Med Scand       Date:  1974-05

5.  Clinical use of furosemide.

Authors:  F C Reubi
Journal:  Ann N Y Acad Sci       Date:  1966-11-22       Impact factor: 5.691

6.  Effectiveness of bumetanide in nephrotic syndrome: a double-blind crossover study with furosemide.

Authors:  K Lau; R DeFronzo; G Morrison; J Rascoff; M Goldberg; Z S Agus
Journal:  J Clin Pharmacol       Date:  1976-10       Impact factor: 3.126

7.  Bumetanide, a new loop diuretic.

Authors:  S Carrière; R Dandavino
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

  7 in total
  4 in total

1.  Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study.

Authors:  Gaurav Kapur; Rudolph P Valentini; Abubakr A Imam; Tej K Mattoo
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

Review 2.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

Review 3.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.

Authors:  Agnes Trautmann; Marina Vivarelli; Susan Samuel; Debbie Gipson; Aditi Sinha; Franz Schaefer; Ng Kar Hui; Olivia Boyer; Moin A Saleem; Luciana Feltran; Janina Müller-Deile; Jan Ulrich Becker; Francisco Cano; Hong Xu; Yam Ngo Lim; William Smoyer; Ifeoma Anochie; Koichi Nakanishi; Elisabeth Hodson; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2020-05-07       Impact factor: 3.714

Review 4.  Off-Label Use of Bumetanide for Brain Disorders: An Overview.

Authors:  Shivani C Kharod; Seok Kyu Kang; Shilpa D Kadam
Journal:  Front Neurosci       Date:  2019-04-24       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.